计算机认知矫正(CCRT)治疗慢性精神分裂症认知功能损害的不同治疗方案比较研究

注册号:

Registration number:

ChiCTR2000035746 

最近更新日期:

Date of Last Refreshed on:

2020-08-17 00:06:28 

注册时间:

Date of Registration:

2020-08-16 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

计算机认知矫正(CCRT)治疗慢性精神分裂症认知功能损害的不同治疗方案比较研究

Public title:

A Comparative Study on Computerized Cognitive Remediaiton Therapy for Cognitive Impairment in Patients with Chronic Schizophrenia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

计算机认知矫正(CCRT)治疗慢性精神分裂症认知功能损害的不同治疗方案比较研究

Scientific title:

A Comparative Study on Computerized Cognitive Remediaiton Therapy for Cognitive Impairment in Patients with Chronic Schizophrenia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

黄书才 

研究负责人:

黄书才 

Applicant:

Huang Shucai 

Study leader:

Huang Shucai 

申请注册联系人电话:

Applicant telephone:

+86 17330633129

研究负责人电话:

Study leader's
telephone:

+86 17330633129

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

schuang1986@126.com

研究负责人电子邮件:

Study leader's E-mail:

schuang1986@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

安徽省芜湖市弋江区乌霞山路1号

研究负责人通讯地址:

安徽省芜湖市弋江区乌霞山路1号

Applicant address:

1 Wuxiashan Road, Yijiang District, Wuhu, Anhui, China

Study leader's address:

1 Wuxiashan Road, Yijiang District, Wuhu, Anhui, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

芜湖市第四人民医院

Applicant's institution:

The Fourth People's Hospital of Wuhu

研究负责人所在单位:

芜湖市第四人民医院

Affiliation of the Leader:

The Fourth People's Hospital of Wuhu

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2018001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

芜湖市第四人民医院伦理委员会

Name of the ethic committee:

IRB of the Fourth People's Hospital of Wuhu

伦理委员会批准日期:

Date of approved by ethic committee:

2018-04-06 00:00:00

伦理委员会联系人:

梁可美

Contact Name of the ethic committee:

Liang Kemei

伦理委员会联系地址:

安徽省芜湖市弋江区乌霞山路1号

Contact Address of the ethic committee:

1 Wuxiashan Road, Yijiang District, Wuhu, Anhui, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 18909630757

伦理委员会联系人邮箱:

Contact email of the ethic committee:

956205071@qq.com

研究实施负责(组长)单位:

芜湖市第四人民医院

Primary sponsor:

The Fourth People's Hospital of Wuhu

研究实施负责(组长)单位地址:

安徽省芜湖市弋江区乌霞山路1号

Primary sponsor's address:

1 Wuxiashan Road, Yijiang District, Wuhu, Anhui, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽

市(区县):

芜湖

Country:

China

Province:

Anhui

City:

Wuhu

单位(医院):

芜湖市第四人民医院

具体地址:

弋江区乌霞山路1号

Institution
hospital:

The Fourth People's Hospital of Wuhu

Address:

1 Wuxiashan Road, Yijiang District

经费或物资来源:

芜湖市科技局科技成果转化项目

Source(s) of funding:

Science and Technology Achievement Transformation Project, Science and Technology Bureau of Wuhu

研究疾病:

慢性精神分裂症  

Target disease:

Chronic schizophrenia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1)探寻 CCRT 治疗服药期慢性精神分裂症患者认知损害的合理方案; 2)探讨 CCRT 治疗服药期慢性精神分裂症患者认知功能的部分生理学机制; 3)探寻 CCRT 对服药期慢性精神分裂症患者疗效的相关影响因素。  

Objectives of Study:

1) To explore a reasonable plan for CCRT to treat cognitive impairment in patients with chronic schizophrenia; 2) To explore some physiological mechanisms of CCRT in the treatment of patients with chronic schizophrenia; 3) To explore the relevant influencing factors of the efficacy of CCRT on patients with chronic schizophrenia.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

① 伴精神发育迟滞或脑器质性疾病患者;
② 严重衰退或冲动兴奋不合作;
③ 伴发严重的抑郁、焦虑和物质滥用;
④ 存在听觉或/视觉感知障碍;
⑤ 严重的躯体疾病或药物副作用,无法进行CCRT治疗;
⑥ 孕期或哺乳期妇女。

Exclusion criteria:

1. To be with psychic development delayed or brain organic diseases;
2. To be seriously fading or not cooperation due to impulse, exciting;
3. To be with serious depression, anxiety and drug abuse;
4. To be with auditory sense or sight esthesia defect;
5. To be with serious body disease or drug adverse caused unable to accept CCRT;
6. Pregnancy or feeding woman.

研究实施时间:

Study execute time:

From 2020-08-24 00:00:00 To 2020-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-08-24 00:00:00 To 2020-09-30 00:00:00

干预措施:

Interventions:

组别:

干预组A

样本量:

30

Group:

Group A

Sample size:

干预措施:

每周5次运动康复+每周1次CCRT治疗

干预措施代码:

A

Intervention:

Physical exercise five times per week and CCRT treatment once a week

Intervention code:

组别:

干预组B

样本量:

30

Group:

Group B

Sample size:

干预措施:

每周5次运动康复+每周2次CCRT治疗

干预措施代码:

B

Intervention:

Physical exercise five times per week and CCRT treatment twice a week

Intervention code:

组别:

干预组C

样本量:

30

Group:

Group C

Sample size:

干预措施:

每周3次CCRT治疗

干预措施代码:

C

Intervention:

Physical exercise five times per week and CCRT treatment 3 times a week

Intervention code:

组别:

对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

无CCRT治疗

干预措施代码:

HC

Intervention:

No Physical exercise and CCRT treatment

Intervention code:

组别:

运动康复组

样本量:

30

Group:

Group PE

Sample size:

干预措施:

每周5次运动康复训练

干预措施代码:

PE

Intervention:

Only physical exercise five times per week

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

安徽 

市(区县):

芜湖 

Country:

China

Province:

Anhui

City:

Wuhu

单位(医院):

芜湖市第四人民医院 

单位级别:

三甲 

Institution
hospital:

The Fourth People's Hospital of Wuhu

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

认知功能

指标类型:

主要指标

Outcome:

Cognitive function

Type:

Primary indicator

测量时间点:

基线、干预第4周、干预第8周及干预第12周

测量方法:

计算机软件及问卷量表评估

Measure time point of outcome:

Baseline, 4th week of intervention, 8th week of intervention, and 12th week of intervention

Measure method:

Computer software and questionnaire assessment

指标中文名:

血清脑源性神经营养因子

指标类型:

次要指标

Outcome:

Serum brain-derived neurotrophic factor

Type:

Secondary indicator

测量时间点:

基线、干预第4周、干预第8周及干预第12周

测量方法:

酶联免疫法

Measure time point of outcome:

Baseline, 4th week of intervention, 8th week of intervention, and 12th week of intervention

Measure method:

Enzyme-linked immunosorbent assay (ELISA)

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 55 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由经过培训的高年资精神科医师采用随机数字表进行随机分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomized grouping was performed by trained senior psychiatrists using a random number table.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

仅对负责数据分析的研究者设盲。

Blinding:

Only the researchers responsible for data analysis were blinded.

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2021年6月31日前在芜湖市第四人民医院官网科研频道进行网络公开(http://www.wuhusy.com/list)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Before June 31, 2021, the data will be publicly available on the scientific research channel of the Fourth People's Hospital of Wuhu.(http://www.wuhusy.com/list/?65_1.html)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

经过培训的高年资精神科医师进行CRF的数据采集,CRF表由专人保管,双匙进入。本研究未录入电子采集和管理系统。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The trained senior psychiatrist performs data collection of CRF, and the CRF form is kept by a special person, and double-keyed. This study was not entered into an electronic collection and management system.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-08-16 23:56:11